Table 3.

Response Assessment for AG-ITP

Response Assessment	Patients			Response Duration (months)
	No.	No. Evaluable	%	Median	Range
Major response	40	55	73	11.3	1.7-105.6+
CR	19	55	35	12.9	7.2-105.6+
PR	21	55	38	10.2	1.7-68.2+
Disease category*
Locally advanced	27	34	79	12.1	1.7-105.6+
Local recurrence	2	2	100	14.1†	11.1-17.1
Distant metastases	10	18	56	8.2	3.8-63

Abbreviations: AG-ITP, doxorubicin plus gemcitabine followed by ifosfamide, paclitaxel, and cisplatin; CR, complete response; PR, partial response.

^*One patient with a local recurrence and distant metastatic disease had a PR with a response duration of 13.27 months.

^†Mean is 14.1 months.